TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Bolus Versus Prolonged Infusion of Meropenem in Newborn With Late Onset Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Neonates admitted to the neonatal care unit (NCU) who suffer from late onset sepsis (LOS) at admission or during their NICU stay and receive meropenem for at least four days~Exclusion Criteria:~* Acute or chronic renal failure~* Hypersensitivity or allergy to meropenem

- Gender: ALL
- Minimum Age: 3 Days
- Maximum Age: 4 Weeks
- Healthy Volunteers: f

Study Arms:
- Infusion arm (Type: ACTIVE_COMPARATOR): Infants will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection. Each dose will be infused over four hours.
- Bolus group (Type: ACTIVE_COMPARATOR): Infants will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection. Each dose will be infused over thirty minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Sugar-Sweetened Beverage Health Warnings

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Consume at least 12oz/week of sugar-sweetened beverages during the past month~* Be able to read and speak English~Exclusion Criteria:~* Under the age of 18 years~* Consume less than 12 ounces/week of sugar-sweetened beverages during the past month~* Unable to read or speak English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Sugar-Sweetened Beverage Health Warning Label (Type: EXPERIMENTAL): None
- Neutral Label (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis of asthma~* Reversibility \>12% after inhalation of 200 µg Salbutamol~* willingness and ability to complete daily record card on daily basis and to measure morning PEF on daily basis~* 80% compliance in diary card completion asthma control status: Uncontrolled based on the GOAL criteria~Exclusion criteria:~* Change of asthma medication during the last 4 weeks~* Asthma exacerbation characterized by use of oral corticoids during the last 3 months Pretreatment with inhaled corticosteroids more than 500 mcg Beclometasondipropionat or equivalent per day or other controller therapy during the last 3 months~* upper or lower respiratory tract infection during the RUN-IN period moderate or severe asthma exacerbation during the RUN-IN period~* Non compliance with use of Discus, PEF-meter and incomplete diary card data

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SFC 50/250 mcg (Type: EXPERIMENTAL): Participants received the combination product, fluticasone 250 microgram (mcg) plus salmeterol 50 mcg (SFC 50/250 mcg) for 12 weeks. Study treatment was received using DISKUS™ powder inhalers, one dose in morning and evening. Study medication was dispensed at visits 3, 4, and 5 for 30 days each. The participants were provided with salbutamol rescue medication if they developed acute asthmatic symptoms. This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol. Use of rescue medications was recorded in the participant's asthma diaries. Stable dosages of other concomitant medications were allowed if they had no impact on the outcome criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPill

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 50-79 years old~* Enrollment in the Golestan Cohort Study~Exclusion Criteria:~1. Hypersensitivity to any of PolyPill components:~   1. Hypersensitivity to Non-steroidal anti-inflammatory agents~  2. Hypersensitivity to statins~  3. Hypersensitivity to hydrochlorothiazide or sulfonamides~  4. Hypersensitivity to enalapril and valsartan~2. Past medical history of angioedema~3. Medical history of GI bleeding or peptic ulcer in the last 3 months~4. Pregnancy or lactation~5. Bleeding disorders such as hemophilia~6. Receiving anticoagulation therapy~7. Alcohol consumption greater than 40gr/week~8. Advanced liver disease~9. Uncontrolled seizures~10. Asthma with any of the following criteria present:~    1. Daily symptoms~   2. Asthmatic attacks waking the patient from sleep more than once a week~   3. History of nasal polyps~   4. Aspirin sensitive asthma~   5. Presence of rhinitis symptoms not due to infection~11. Past medical history of gout~12. Serum creatinine values above 2 mg/dL or a Glomerular Filtration Rate (GFR) below 30 mL/min~13. Hemoglobin concentrations below 11 g/dL for males and 10 g/dL for females~14. BP \< 90/60~15. Debilitating medical/mental disorders affecting medication compliance (including psychosis, disabilities, and blindness)~16. Past medical history of stroke

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- PolyPill (Type: ACTIVE_COMPARATOR): PolyPill once daily and Minimal Care
- Minimal care (Type: ACTIVE_COMPARATOR): Minimal care.
- Usual care (Type: NO_INTERVENTION): Basic primary health care provided by the local physicians and Community Health Workers consistent with the current Iranian Health Care System guidelines.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed ICF (Informed Consent Form)~* Subject-reported history of Drye Eye Disease (DED) in both eyes~* Ability and willingness to follow instructions, including participation in all study assessments and visits~Exclusion Criteria:~* Women who are pregnant, nursing or planning pregnancy~* Unwillingness to submit a blood pregnancy test at screening and the last visit (or early termination visit) if of childbearing potential, or unwillingness to use acceptable means of birth control~* Clinically significant slit-lamp findings or abnormal lid anatomy at screening and Visit 1~* Ocular/peri-ocular malignancy~* History of herpetic keratitis~* Active ocular allergies or ocular allergies that are expected to be active during the study~* Ongoing ocular or systemic infection~* Wear contact lenses within 1 month prior to screening or anticipated use of contact lenses during the study~* Intra-ocular surgery or ocular laser surgery within the previous 6 months, or have planned ocular and/or lid surgeries over the study period~* Presence of uncontrolled systemic diseases~* Presence of known allergy and/or sensitivity to the study drug or saline components~* Use of any topical steroids treatments, topical cyclosporine, lifitegrast, serum tears or topical anti-glaucoma medication within 2 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NOV03 4 times daily (QID) (Type: EXPERIMENTAL): 100% Perfluorohexyloctance solution 4 times daily (QID)
- Placebo 4 times daily (QID) (Type: PLACEBO_COMPARATOR): Saline solution (0.6% sodium chloride solution) 4 times daily (QID)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Stage 3 Fontan Operation Liver Ultrasound Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric patients ages 0-17~* Patients presenting to the University of Michigan for evaluation just before undergoing stage 3 of the Fontan operation~Exclusion Criteria:~* Patients over the age of 17~* Patients who have chronic liver disease (elevation of ALT, AST, or Bilirubin greater than two times the upper limits of normal \>4 weeks)~* Patients who have evidence of liver enlargement or nodularity on prior ultrasound imaging~* Patients who have a history of portal vein or hepatic vein thrombosis~* Patients (parents) who are unwilling to read and sign the informed consent document

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- ARFI Ultrasound (Type: EXPERIMENTAL): This study uses ultrasound scanning with acoustic radiation force impulse shear wave velocity imaging to measure pediatric liver fibrosis. Patients will be children who have had the Fontan operation. This is a non-invasive scan that uses sound waves to create images.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Preoperative and Post Operative Misoprostol Administration on Intraoperative Blood Loss and Postpartum Hemorrhage in CS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~women attending for elective CS.~* Age between 20-35 years.~* Normal placental site~* Normal coagulation profile~* Full term pregnancies(above 37 wks)~* Medically free~* Spinal anesthesia~* Living baby~* Average liquor by U/S~Exclusion Criteria:~* • Women attending for emergency CS~  * .age below 20 or above 35~ * Abnormal placentation (Placenta previa,accrete,increta or percreta)~ * Women with coagulopathy~ * Preterm pregnancies (before 37 wks)~ * Medical disorder (Hypertension,Diabetes, Endocrinal disorder)~ * General anathesia~ * IUFD~ * Oligo or polyhydraminos by U/S

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Routine ecbolic group (Type: ACTIVE_COMPARATOR): 100 patients will receive routine ecbolics ( oxytocin) after delivery of baby
- Misoprostol group (Type: ACTIVE_COMPARATOR): The 100 patients will receive routine ecbolics (oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Variation in Natremia Using Two Different Maintenance Intravenous Fluids in Postsurgical Hospitalized Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Postsurgical children admitted to HGNPE Department of Surgery between january 2010 and october 2011.~Aged 1 month to 16 years. Initial plasma Na between 135-145 mmol/L. Primary route of fluid administration is anticipated to be intravenous, in the first 12 hours following surgery.~Informed consent of parent/guardian.~Exclusion Criteria:~* • Children with illness that have primary fluid and electrolyte imbalance such as:~  * Shock: Defined as acute circulatory failure resulting in decreased tissue perfusion and manifesting as altered sensorium, hypothermia (\<35oC), tachycardia, prolonged capillary filling time (\>3 seconds), hypotension (BP \< 5th percentile for age), oliguria (\<0.5 ml/kg/hr), hypoxemia, hyperlactatemia, requirement of fluid bolus and/ or vasopressors.~ * Diarrhea and Dehydration: Children presenting with diarrhea and features of dehydration: lethargy, irritability and altered sensorium, thirst, decreased urine output, sunken eyes \& dry mucous membranes, loss of skin elasticity.; children with ongoing diarrhea will be excluded even if there is no dehydration.~ * Fluid Overload: Cirrhosis, Congestive heart failure, Acute and Chronic renal failure, Nephrotic syndrome.~    * Hyperglycemia: blood glucose \> 180 mg/ dl.~   * Require ICU admission.~   * Severe Protein Energy Malnutrition: Defined as grade III (50-59% of expected weight for age) and grade IV (less than 50% of expected weight for age) as per IAP classification.~   * Patients in whom either hypotonic or isotonic solutions may be contraindicated/necessary: i.e. specific neurosurgical patients (ie those at risk of increased ICP, e.g. requiring actual brain surgery, ICP monitor or external ventricular drain insertion), patients with diabetic ketoacidosis, acute (≤ 7 days) burns, pre-existing CHF, liver failure or cirrhosis, renal failure.~   * Patients with known pre-existing risk of PNa derangements: DI or SIADH

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- half saline (Type: EXPERIMENTAL): Subjects in this arm will receive 0.45% NaCl/dextrose 5% intravenous (IV) maintenance fluids.
- third saline (Type: ACTIVE_COMPARATOR): Subjects in this arm will receive 0.3% NaCl/dextrose 5% intravenous (IV) maintenance fluids.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Documented or patient reported history (for at least 2 years) of symptomatic cat allergen-triggered asthma with rhinitis with or without conjunctivitis~* No cat exposure at home for the past year and must continue having no exposure at home during the study; cat exposure outside of the home shall be avoided for at least one week prior to any Cat Allergen Challenge and during the defined follow-up period~* Less than 10 pack-years of smoking history~Key Exclusion Criteria:~* Positive human immunodeficiency virus (HIV) test~* Positive hepatitis test (HBsAg and hepatitis C antibody)~* History of significant multiple and/or severe allergies (including latex gloves) or has had an anaphylactic reaction or significant intolerability to prescription or nonprescription drugs or food~* Participation in a prior REGN1908-1909 clinical trial~* History of severe anaphylactic or severe asthmatic reactions to cat exposure~* Active lung disease other than asthma~* Treatment with an investigational drug within 2 months or within 5 half-lives (if known), whichever is longer, prior to screening~* Persistent chronic or recurring acute infection requiring treatment with antibiotics, antivirals, or antifungals, or any untreated respiratory infections within 4 weeks prior to screening~* History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest, and/or hypoxic seizures~* Treatment of asthma requiring systemic (oral or parenteral) corticosteroid treatment more than twice within 12 months or once within 3 months prior to screening or has been hospitalized or has attended the ER/Urgent Care facility for asthma more than twice in prior 12 months before screening.~* History of hypersensitivity to corticosteroids or antihistamines, or drug treatment excipient~Note: Other protocol defined Inclusion/Exclusion Criteria Apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- REGN1908-1909 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Platelet-Rich Plasma Epidural Injection an Emerging Strategy in Lumbar Disc Herniation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 20-55 years~* Having failed conservative treatment for at least 6 weeks~* Visual analogue scale (VAS) of greater than 30~* Confirmed a single-level HNP, corelated to clinical, by MRI.~Exclusion Criteria:~* Previous spine surgery or epidural injection~* Progressive neurological deficit~* Cauda equina~* Coagulopathy-related conditions~* Associated cervical myelopathy~* Systemic bone and joint diseases

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Triamcinolone group (Type: ACTIVE_COMPARATOR): Patients were placed in the prone position. Transforaminal triamcinolone injections were performed under a C-arm fluoroscopy.
- Platelet-rich plasma (Type: EXPERIMENTAL): Patients were placed in the prone position. Transforaminal PRPinjections were performed under a C-arm fluoroscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven diagnosis of colorectal adenocarcinoma~* Metastatic disease present in the liver only.~* Absence of extrahepatic metastases excluded by CT chest, abdomen and pelvis. Indeterminate CT findings may require verification by FDG-PET scanning.~* Liver-only metastases determined to be unresectable at presentation on a pre-treatment liver MRI with an appropriate liver specific contrast (eg. TESLA) by a specialist multidisciplinary team (consisting of medical oncologist, hepatic surgeon and radiologist). Guidelines for determining unresectability include:~* presence of \>4 metastases;~* size \>5cm;~* location and distribution of metastatic disease within the liver unsuitable for resection with clear margins (eg. Involvement of both lobes of liver; invasion of intrahepatic vascular structures);~* extent of liver involvement precluding resection with adequate post-resection residual liver parenchyma volume for viable liver function in the immediate post-operative period;~* inability to retain adequate vascular in flow and out flow to maintain viable liver function.~* No previous treatment for metastatic colorectal cancer, including chemotherapy, targeted or experimental therapies (e.g. anti-VEGF or anti-EGFR), radiotherapy to the liver, or surgery or radiofrequency ablation to liver metastases.~* Feasibility of surgery with curative intent:~* If the primary colorectal tumour is in situ, the primary tumour must also be resectable with curative intent~* Patients presenting with liver metastases only relapse after initially curative resection of their primary colorectal cancer followed by treatment with adjuvant chemotherapy may not be entered into the study if the relapse has occurred within 12 months of completion of adjuvant treatment~* Adequate medical fitness to undergo neoadjuvant treatment and surgery with curative intent (hepatectomy +/- resection of primary tumour, if required)~* Absence of pre-existing liver dysfunction of Childs Pugh Grade B or greater. Patients who are suspected of having pre-existing liver dysfunction due to clinical, biochemical or radiological findings, should have significant liver disease excluded by a liver biopsy prior to study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- This is a single arm study (Type: OTHER): This is a single arm study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete